A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Exclusion Criteria

• •Surgical history of hysterectomy and/or bilateral oophorectomy
• •Chronic pelvic and/or non-pelvic pain not caused by endometriosis that requires chronic analgesic or other chronic therapy
• •Undiagnosed (unexplained), abnormal vaginal bleeding not associated with endometriosis within the past 6 months before screening.
• •Presence of high-risk human papillomavirus (HPV).
• •Has an active sexually transmitted infection (STI) (eg, gonorrhea, chlamydia, or trichomonas).
• •Intends to become pregnant or breast feed during study participation or has a known or suspected pregnancy.
• •History of malignancy (except for basal cell or squamous cell skin cancer) before signing informed consent.
• •History of family history of hereditary abnormal hemoglobin or an enzyme deficiency that can result in methemoglobinemia.
• •Has a medical condition associated with hemolytic anemia
• •Known human immunodeficiency virus infection, and/or acute or active, recurrent/relapsing, or chronic infection (eg, hepatitis A, B, or C virus)
• •Has a clinically significant abnormal ECG or QT interval prolongation
• •Used any medication that is either a sensitive substrate, moderate, or strong inhibitor or inducer of CYP3A4 within 30 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing.